| 1 | 1 | | II |
|---|
| 2 | 2 | | 119THCONGRESS |
|---|
| 3 | 3 | | 1 |
|---|
| 4 | 4 | | STSESSION S. 998 |
|---|
| 5 | 5 | | To authorize the President to enter into trade agreements for the reciprocal |
|---|
| 6 | 6 | | elimination of duties or other import restrictions with respect to medical |
|---|
| 7 | 7 | | goods to contribute to the national security and public health of the |
|---|
| 8 | 8 | | United States, and for other purposes. |
|---|
| 9 | 9 | | IN THE SENATE OF THE UNITED STATES |
|---|
| 10 | 10 | | MARCH12, 2025 |
|---|
| 11 | 11 | | Mr. T |
|---|
| 12 | 12 | | ILLIS(for himself, Mr. COONS, Mr. CORNYN, and Mr. BENNET) intro- |
|---|
| 13 | 13 | | duced the following bill; which was read twice and referred to the Com- |
|---|
| 14 | 14 | | mittee on Finance |
|---|
| 15 | 15 | | A BILL |
|---|
| 16 | 16 | | To authorize the President to enter into trade agreements |
|---|
| 17 | 17 | | for the reciprocal elimination of duties or other import |
|---|
| 18 | 18 | | restrictions with respect to medical goods to contribute |
|---|
| 19 | 19 | | to the national security and public health of the United |
|---|
| 20 | 20 | | States, and for other purposes. |
|---|
| 21 | 21 | | Be it enacted by the Senate and House of Representa-1 |
|---|
| 22 | 22 | | tives of the United States of America in Congress assembled, 2 |
|---|
| 23 | 23 | | SECTION 1. SHORT TITLE. 3 |
|---|
| 24 | 24 | | This Act may be cited as the ‘‘Medical Supply Chain 4 |
|---|
| 25 | 25 | | Resiliency Act’’. 5 |
|---|
| 26 | 26 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 27 | 27 | | ssavage on LAPJG3WLY3PROD with BILLS 2 |
|---|
| 28 | 28 | | •S 998 IS |
|---|
| 29 | 29 | | SEC. 2. FINDINGS; SENSE OF CONGRESS. 1 |
|---|
| 30 | 30 | | (a) F |
|---|
| 31 | 31 | | INDINGS.—Congress makes the following find-2 |
|---|
| 32 | 32 | | ings: 3 |
|---|
| 33 | 33 | | (1) The COVID–19 pandemic created signifi-4 |
|---|
| 34 | 34 | | cant demand pressures on the global medical supply 5 |
|---|
| 35 | 35 | | chain. 6 |
|---|
| 36 | 36 | | (2) According to a December 2020 report by 7 |
|---|
| 37 | 37 | | the United States International Trade Commission, 8 |
|---|
| 38 | 38 | | global demand significantly exceeded available sup-9 |
|---|
| 39 | 39 | | ply of many goods critical for the response to the 10 |
|---|
| 40 | 40 | | COVID–19 pandemic (in this section referred to as 11 |
|---|
| 41 | 41 | | ‘‘COVID–19 critical goods’’). Health care providers 12 |
|---|
| 42 | 42 | | in the United States faced difficulties in procuring 13 |
|---|
| 43 | 43 | | such goods in sufficient quantities. Foreign export 14 |
|---|
| 44 | 44 | | restrictions on finished drugs and active pharma-15 |
|---|
| 45 | 45 | | ceutical ingredients may have contributed to stress 16 |
|---|
| 46 | 46 | | on the supply of some critical COVID–19 treatment 17 |
|---|
| 47 | 47 | | drugs (including anti-infective products), as well as 18 |
|---|
| 48 | 48 | | hormone medications and vitamins. 19 |
|---|
| 49 | 49 | | (3) According to the McKinsey Global Institute, 20 |
|---|
| 50 | 50 | | during the 20 years preceding the date of the enact-21 |
|---|
| 51 | 51 | | ment of this Act, pharmaceutical supply chains have 22 |
|---|
| 52 | 52 | | become more globally dispersed and many generic 23 |
|---|
| 53 | 53 | | small-molecule products have shifted to lower-cost 24 |
|---|
| 54 | 54 | | production locations, some of which have been iden-25 |
|---|
| 55 | 55 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 56 | 56 | | ssavage on LAPJG3WLY3PROD with BILLS 3 |
|---|
| 57 | 57 | | •S 998 IS |
|---|
| 58 | 58 | | tified as posing a threat to the national security of 1 |
|---|
| 59 | 59 | | the United States. 2 |
|---|
| 60 | 60 | | (4) According to the Organisation for Economic 3 |
|---|
| 61 | 61 | | Co-operation and Development, while the United 4 |
|---|
| 62 | 62 | | States is one of the largest exporters of COVID–19 5 |
|---|
| 63 | 63 | | critical goods, it is also one of the largest importers 6 |
|---|
| 64 | 64 | | of those goods. 7 |
|---|
| 65 | 65 | | (5) The World Trade Organization has found 8 |
|---|
| 66 | 66 | | that, while the United States, Germany, and the 9 |
|---|
| 67 | 67 | | People’s Republic of China are all major producers 10 |
|---|
| 68 | 68 | | and importers of COVID–19 critical goods, United 11 |
|---|
| 69 | 69 | | States import partners are less diversified compared 12 |
|---|
| 70 | 70 | | to Germany and the People’s Republic of China. In 13 |
|---|
| 71 | 71 | | the United States, more than half of its imports of 14 |
|---|
| 72 | 72 | | COVID–19 critical goods came from only 3 part-15 |
|---|
| 73 | 73 | | ners—the People’s Republic of China (30.6 percent), 16 |
|---|
| 74 | 74 | | Mexico (15.3 percent), and Malaysia (9.0 percent). 17 |
|---|
| 75 | 75 | | (6) While some of the countries in which med-18 |
|---|
| 76 | 76 | | ical supply manufacturing occurs are reliable sup-19 |
|---|
| 77 | 77 | | pliers and allies to the United States, others have 20 |
|---|
| 78 | 78 | | adopted or maintained policies that make United 21 |
|---|
| 79 | 79 | | States supply less secure. 22 |
|---|
| 80 | 80 | | (b) S |
|---|
| 81 | 81 | | ENSE OFCONGRESS.—It is the sense of Con-23 |
|---|
| 82 | 82 | | gress that, given the threat to national security and public 24 |
|---|
| 83 | 83 | | health that could arise if the United States is unable to 25 |
|---|
| 84 | 84 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 85 | 85 | | ssavage on LAPJG3WLY3PROD with BILLS 4 |
|---|
| 86 | 86 | | •S 998 IS |
|---|
| 87 | 87 | | swiftly respond to significant demand surges for medical 1 |
|---|
| 88 | 88 | | products in a future pandemic, it is critical that the 2 |
|---|
| 89 | 89 | | United States diversify its trade relationships and 3 |
|---|
| 90 | 90 | | prioritize partners that adopt and maintain reliable supply 4 |
|---|
| 91 | 91 | | chain policies. 5 |
|---|
| 92 | 92 | | SEC. 3. PURPOSES. 6 |
|---|
| 93 | 93 | | The purposes of this Act are— 7 |
|---|
| 94 | 94 | | (1) to improve overall medical supply chain re-8 |
|---|
| 95 | 95 | | silience for the United States by establishing a 9 |
|---|
| 96 | 96 | | framework to enhance medical supply chains with 10 |
|---|
| 97 | 97 | | trusted trade partners; 11 |
|---|
| 98 | 98 | | (2) to enhance supply chain security related to 12 |
|---|
| 99 | 99 | | technology transfer and intellectual property protec-13 |
|---|
| 100 | 100 | | tion; 14 |
|---|
| 101 | 101 | | (3) to diversify and expand supplier networks to 15 |
|---|
| 102 | 102 | | ensure a reliable supply of medical goods, especially 16 |
|---|
| 103 | 103 | | in the event of emergency situations; 17 |
|---|
| 104 | 104 | | (4) to eliminate unnecessary trade barriers and 18 |
|---|
| 105 | 105 | | distortions that weaken or disrupt medical supply 19 |
|---|
| 106 | 106 | | chains; 20 |
|---|
| 107 | 107 | | (5) to expedite cross-border movement of crit-21 |
|---|
| 108 | 108 | | ical medical goods; 22 |
|---|
| 109 | 109 | | (6) to foster international collaboration, encour-23 |
|---|
| 110 | 110 | | age new investments, promote cooperation and part-24 |
|---|
| 111 | 111 | | nership in public and private research and develop-25 |
|---|
| 112 | 112 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 113 | 113 | | ssavage on LAPJG3WLY3PROD with BILLS 5 |
|---|
| 114 | 114 | | •S 998 IS |
|---|
| 115 | 115 | | ment efforts, facilitate data flows for life science re-1 |
|---|
| 116 | 116 | | search and development, and expand manufacturing 2 |
|---|
| 117 | 117 | | capacities for medical devices and pharmaceutical 3 |
|---|
| 118 | 118 | | goods; 4 |
|---|
| 119 | 119 | | (7) to promote regulatory cooperation with re-5 |
|---|
| 120 | 120 | | spect to manufacturing of medical goods; 6 |
|---|
| 121 | 121 | | (8) to increase access to government procure-7 |
|---|
| 122 | 122 | | ment markets for medical goods; 8 |
|---|
| 123 | 123 | | (9) to encourage adoption of and adherence to 9 |
|---|
| 124 | 124 | | good regulatory practices related to medical goods; 10 |
|---|
| 125 | 125 | | (10) to enable greater transparency, regulatory 11 |
|---|
| 126 | 126 | | harmonization, and reliance in authorization and li-12 |
|---|
| 127 | 127 | | censing procedures for medical devices and pharma-13 |
|---|
| 128 | 128 | | ceutical goods; 14 |
|---|
| 129 | 129 | | (11) to facilitate trade in medical goods to the 15 |
|---|
| 130 | 130 | | most efficient and practicable extent possible; and 16 |
|---|
| 131 | 131 | | (12) to identify current production capacities, 17 |
|---|
| 132 | 132 | | address potential weaknesses, and improve overall 18 |
|---|
| 133 | 133 | | resilience. 19 |
|---|
| 134 | 134 | | SEC. 4. DEFINITIONS. 20 |
|---|
| 135 | 135 | | In this Act: 21 |
|---|
| 136 | 136 | | (1) A |
|---|
| 137 | 137 | | PPROPRIATE COMMITTEES OF CON -22 |
|---|
| 138 | 138 | | GRESS.—The term ‘‘appropriate committees of Con-23 |
|---|
| 139 | 139 | | gress’’ means— 24 |
|---|
| 140 | 140 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 141 | 141 | | ssavage on LAPJG3WLY3PROD with BILLS 6 |
|---|
| 142 | 142 | | •S 998 IS |
|---|
| 143 | 143 | | (A) the Committee on Finance of the Sen-1 |
|---|
| 144 | 144 | | ate; and 2 |
|---|
| 145 | 145 | | (B) the Committee on Ways and Means of 3 |
|---|
| 146 | 146 | | the House of Representatives. 4 |
|---|
| 147 | 147 | | (2) C |
|---|
| 148 | 148 | | OUNTRY.—The term ‘‘country’’ means— 5 |
|---|
| 149 | 149 | | (A) any foreign country or territory, in-6 |
|---|
| 150 | 150 | | cluding any overseas dependent territory or pos-7 |
|---|
| 151 | 151 | | session of a foreign country; or 8 |
|---|
| 152 | 152 | | (B) the Trust Territory of the Pacific Is-9 |
|---|
| 153 | 153 | | lands. 10 |
|---|
| 154 | 154 | | (3) M |
|---|
| 155 | 155 | | EDICAL DEVICE.—The term ‘‘medical de-11 |
|---|
| 156 | 156 | | vice’’ means a device, as defined in section 201 of 12 |
|---|
| 157 | 157 | | the Federal Food, Drug, and Cosmetic Act (21 13 |
|---|
| 158 | 158 | | U.S.C. 321), that is intended for use in humans. 14 |
|---|
| 159 | 159 | | (4) M |
|---|
| 160 | 160 | | EDICAL GOOD.—The term ‘‘medical good’’ 15 |
|---|
| 161 | 161 | | means any medical device, pharmaceutical good, or 16 |
|---|
| 162 | 162 | | input for such a device or good. 17 |
|---|
| 163 | 163 | | (5) M |
|---|
| 164 | 164 | | EDICAL SUPPLY CHAIN.—The term ‘‘med-18 |
|---|
| 165 | 165 | | ical supply chain’’ means any activities involving de-19 |
|---|
| 166 | 166 | | sign, procurement, manufacturing, production, dis-20 |
|---|
| 167 | 167 | | tribution, operation, or management related to med-21 |
|---|
| 168 | 168 | | ical goods. 22 |
|---|
| 169 | 169 | | (6) P |
|---|
| 170 | 170 | | HARMACEUTICAL GOOD .—The term ‘‘phar-23 |
|---|
| 171 | 171 | | maceutical good’’ means a drug, as defined in sec-24 |
|---|
| 172 | 172 | | tion 201 of the Federal Food, Drug, and Cosmetic 25 |
|---|
| 173 | 173 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 174 | 174 | | ssavage on LAPJG3WLY3PROD with BILLS 7 |
|---|
| 175 | 175 | | •S 998 IS |
|---|
| 176 | 176 | | Act (21 U.S.C. 321), that is intended for use in hu-1 |
|---|
| 177 | 177 | | mans. 2 |
|---|
| 178 | 178 | | (7) T |
|---|
| 179 | 179 | | RADE REPRESENTATIVE .—The term 3 |
|---|
| 180 | 180 | | ‘‘Trade Representative’’ means the United States 4 |
|---|
| 181 | 181 | | Trade Representative. 5 |
|---|
| 182 | 182 | | (8) T |
|---|
| 183 | 183 | | RUSTED TRADE PARTNER .—The term 6 |
|---|
| 184 | 184 | | ‘‘trusted trade partner’’ means any country that has 7 |
|---|
| 185 | 185 | | entered into an agreement with the United States 8 |
|---|
| 186 | 186 | | under section 5. 9 |
|---|
| 187 | 187 | | (9) T |
|---|
| 188 | 188 | | RUSTED TRADE PARTNER AGREEMENT .— 10 |
|---|
| 189 | 189 | | The term ‘‘trusted trade partner agreement’’ means 11 |
|---|
| 190 | 190 | | an agreement entered into under section 5. 12 |
|---|
| 191 | 191 | | SEC. 5. AUTHORITY TO ENTER INTO TRUSTED TRADE PART-13 |
|---|
| 192 | 192 | | NER AGREEMENTS. 14 |
|---|
| 193 | 193 | | (a) I |
|---|
| 194 | 194 | | NGENERAL.—Whenever the President deter-15 |
|---|
| 195 | 195 | | mines, based on the considerations set forth in subsection 16 |
|---|
| 196 | 196 | | (b), that the reciprocal elimination of existing duties or 17 |
|---|
| 197 | 197 | | other import restrictions of a country or countries and the 18 |
|---|
| 198 | 198 | | United States with respect to medical goods would con-19 |
|---|
| 199 | 199 | | tribute to the national security and public health of the 20 |
|---|
| 200 | 200 | | United States, the President may, subject to the require-21 |
|---|
| 201 | 201 | | ments under section 6— 22 |
|---|
| 202 | 202 | | (1) negotiate, enter into, and enforce a trusted 23 |
|---|
| 203 | 203 | | trade partner agreement with the country or coun-24 |
|---|
| 204 | 204 | | tries; and 25 |
|---|
| 205 | 205 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 206 | 206 | | ssavage on LAPJG3WLY3PROD with BILLS 8 |
|---|
| 207 | 207 | | •S 998 IS |
|---|
| 208 | 208 | | (2) proclaim such modification of any existing 1 |
|---|
| 209 | 209 | | duty, such continuance of existing duty-free or excise 2 |
|---|
| 210 | 210 | | treatment, or such additional duties, as the Presi-3 |
|---|
| 211 | 211 | | dent determines to be required or appropriate to 4 |
|---|
| 212 | 212 | | carry out any such trade agreement. 5 |
|---|
| 213 | 213 | | (b) C |
|---|
| 214 | 214 | | ONSIDERATIONS.—In determining whether to 6 |
|---|
| 215 | 215 | | enter into negotiations for a trusted trade partner agree-7 |
|---|
| 216 | 216 | | ment with a country pursuant to subsection (a), the Presi-8 |
|---|
| 217 | 217 | | dent shall take into account whether the government of 9 |
|---|
| 218 | 218 | | the country has— 10 |
|---|
| 219 | 219 | | (1) expressed a desire to enter into such an 11 |
|---|
| 220 | 220 | | agreement; 12 |
|---|
| 221 | 221 | | (2) demonstrated a commitment to contribute 13 |
|---|
| 222 | 222 | | to global health security, including the national secu-14 |
|---|
| 223 | 223 | | rity of the United States and the health of United 15 |
|---|
| 224 | 224 | | States citizens, by maintaining open trade in medical 16 |
|---|
| 225 | 225 | | goods during a public health emergency, including to 17 |
|---|
| 226 | 226 | | enable research, development, and manufacturing of 18 |
|---|
| 227 | 227 | | those goods; 19 |
|---|
| 228 | 228 | | (3) adhered to and implemented the commit-20 |
|---|
| 229 | 229 | | ments and obligations under existing free trade 21 |
|---|
| 230 | 230 | | agreements to which that country and the United 22 |
|---|
| 231 | 231 | | States are parties; 23 |
|---|
| 232 | 232 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00008 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 233 | 233 | | ssavage on LAPJG3WLY3PROD with BILLS 9 |
|---|
| 234 | 234 | | •S 998 IS |
|---|
| 235 | 235 | | (4) implemented measures to reduce or elimi-1 |
|---|
| 236 | 236 | | nate unnecessary trade barriers and distorting prac-2 |
|---|
| 237 | 237 | | tices affecting medical goods; 3 |
|---|
| 238 | 238 | | (5) maintained the rule of law by enacting and 4 |
|---|
| 239 | 239 | | enforcing laws and regulations in a clear, publicized, 5 |
|---|
| 240 | 240 | | transparent, and nondiscriminatory manner; 6 |
|---|
| 241 | 241 | | (6) adopted and enforced laws that provide ade-7 |
|---|
| 242 | 242 | | quate and effective protection of intellectual property 8 |
|---|
| 243 | 243 | | rights reflecting a standard of protection similar to 9 |
|---|
| 244 | 244 | | that found under United States law; and 10 |
|---|
| 245 | 245 | | (7) agreed to recognize and promote good regu-11 |
|---|
| 246 | 246 | | latory practices related to medical goods. 12 |
|---|
| 247 | 247 | | (c) T |
|---|
| 248 | 248 | | RUSTEDTRADEPARTNERAGREEMENTS.—A 13 |
|---|
| 249 | 249 | | trusted trade partner agreement may, with respect to 14 |
|---|
| 250 | 250 | | medical goods, provide for— 15 |
|---|
| 251 | 251 | | (1) reduction or elimination of duties, quotas, 16 |
|---|
| 252 | 252 | | and other trade barriers that undermine the national 17 |
|---|
| 253 | 253 | | security and public health of the United States by 18 |
|---|
| 254 | 254 | | disincentivizing research, development, and manufac-19 |
|---|
| 255 | 255 | | turing in the United States or in countries that are 20 |
|---|
| 256 | 256 | | reliable suppliers of medical goods to the United 21 |
|---|
| 257 | 257 | | States; 22 |
|---|
| 258 | 258 | | (2) diversification and expansion of supplier 23 |
|---|
| 259 | 259 | | networks to secure a reliable supply of medical 24 |
|---|
| 260 | 260 | | goods; 25 |
|---|
| 261 | 261 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00009 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 262 | 262 | | ssavage on LAPJG3WLY3PROD with BILLS 10 |
|---|
| 263 | 263 | | •S 998 IS |
|---|
| 264 | 264 | | (3) harmonization or convergence of regulatory 1 |
|---|
| 265 | 265 | | procedures, regulatory reliance, inspection coopera-2 |
|---|
| 266 | 266 | | tion, and adoption of international standards (such 3 |
|---|
| 267 | 267 | | as to streamline post-approval changes) to expedite 4 |
|---|
| 268 | 268 | | cross-border movement of medical goods; 5 |
|---|
| 269 | 269 | | (4) increased access to government procurement 6 |
|---|
| 270 | 270 | | markets for medical goods and, in the case of a mul-7 |
|---|
| 271 | 271 | | tilateral agreement entered into under the auspices 8 |
|---|
| 272 | 272 | | of the World Trade Organization, membership in the 9 |
|---|
| 273 | 273 | | Agreement on Government Procurement of the 10 |
|---|
| 274 | 274 | | World Trade Organization referred to in section 11 |
|---|
| 275 | 275 | | 101(d)(17) of the Uruguay Round Agreements Act 12 |
|---|
| 276 | 276 | | (19 U.S.C. 3511(d)(17)); 13 |
|---|
| 277 | 277 | | (5) adequate and effective protection of intellec-14 |
|---|
| 278 | 278 | | tual property rights for medical goods reflecting a 15 |
|---|
| 279 | 279 | | standard of protection similar to that found under 16 |
|---|
| 280 | 280 | | United States law; 17 |
|---|
| 281 | 281 | | (6) regulatory cooperation on manufacturing 18 |
|---|
| 282 | 282 | | standards for medical goods; 19 |
|---|
| 283 | 283 | | (7) a collaboration framework to promote public 20 |
|---|
| 284 | 284 | | and private research and development efforts related 21 |
|---|
| 285 | 285 | | to medical goods, including facilitation of data flows 22 |
|---|
| 286 | 286 | | for life science research and development; 23 |
|---|
| 287 | 287 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00010 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 288 | 288 | | ssavage on LAPJG3WLY3PROD with BILLS 11 |
|---|
| 289 | 289 | | •S 998 IS |
|---|
| 290 | 290 | | (8) adherence to good regulatory practices for 1 |
|---|
| 291 | 291 | | sound, affordable, and efficient regulation of medical 2 |
|---|
| 292 | 292 | | goods; 3 |
|---|
| 293 | 293 | | (9) promotion of regulatory compatibility and 4 |
|---|
| 294 | 294 | | cooperation to facilitate trade and investment related 5 |
|---|
| 295 | 295 | | to medical goods and accelerate manufacturing of 6 |
|---|
| 296 | 296 | | such goods during a public health emergency; and 7 |
|---|
| 297 | 297 | | (10) exemption of parties to the agreement 8 |
|---|
| 298 | 298 | | from trade-restrictive measures imposed with respect 9 |
|---|
| 299 | 299 | | to medical goods during a public health emergency. 10 |
|---|
| 300 | 300 | | (d) R |
|---|
| 301 | 301 | | EPORTREQUIRED.—Not later than 180 days 11 |
|---|
| 302 | 302 | | after the date of the enactment of this Act, and every 180 12 |
|---|
| 303 | 303 | | days thereafter, the President shall submit to Congress 13 |
|---|
| 304 | 304 | | a report on the status of negotiations conducted under 14 |
|---|
| 305 | 305 | | subsection (a) for trusted trade partner agreements. 15 |
|---|
| 306 | 306 | | SEC. 6. CONGRESSIONAL OVERSIGHT, NOTICE, CONSULTA-16 |
|---|
| 307 | 307 | | TIONS, ACCESS TO INFORMATION, AND RE-17 |
|---|
| 308 | 308 | | VIEW. 18 |
|---|
| 309 | 309 | | (a) N |
|---|
| 310 | 310 | | OTICE.—Not later than 60 days before initi-19 |
|---|
| 311 | 311 | | ating negotiations with a trusted trade partner under sec-20 |
|---|
| 312 | 312 | | tion 5(a) for a trusted trade partner agreement, the Presi-21 |
|---|
| 313 | 313 | | dent shall submit to Congress written notice of the inten-22 |
|---|
| 314 | 314 | | tion of the President to enter into the negotiations, which 23 |
|---|
| 315 | 315 | | shall include the date negotiations will begin and the trust-24 |
|---|
| 316 | 316 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00011 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 317 | 317 | | ssavage on LAPJG3WLY3PROD with BILLS 12 |
|---|
| 318 | 318 | | •S 998 IS |
|---|
| 319 | 319 | | ed trade partner with whom the President seeks to enter 1 |
|---|
| 320 | 320 | | into the agreement. 2 |
|---|
| 321 | 321 | | (b) C |
|---|
| 322 | 322 | | ONSULTATION WITHMEMBERS OF CON-3 |
|---|
| 323 | 323 | | GRESS.— 4 |
|---|
| 324 | 324 | | (1) C |
|---|
| 325 | 325 | | ONSULTATION DURING NEGOTIATIONS AND 5 |
|---|
| 326 | 326 | | ACCESS TO INFORMATION .—In the course of negotia-6 |
|---|
| 327 | 327 | | tions under section 5(a) for a trusted trade partner 7 |
|---|
| 328 | 328 | | agreement, the Trade Representative shall— 8 |
|---|
| 329 | 329 | | (A) meet upon request with the appro-9 |
|---|
| 330 | 330 | | priate committees of Congress regarding negoti-10 |
|---|
| 331 | 331 | | ating objectives, the status of negotiations in 11 |
|---|
| 332 | 332 | | progress, and potential effects to the laws of 12 |
|---|
| 333 | 333 | | the United States with respect to the agree-13 |
|---|
| 334 | 334 | | ment; 14 |
|---|
| 335 | 335 | | (B) upon request by the appropriate com-15 |
|---|
| 336 | 336 | | mittees of Congress, provide access to pertinent 16 |
|---|
| 337 | 337 | | documents relating to the negotiations; and 17 |
|---|
| 338 | 338 | | (C) consult closely and on a timely basis 18 |
|---|
| 339 | 339 | | with, and keep fully apprised of the negotia-19 |
|---|
| 340 | 340 | | tions, the appropriate committees of Congress. 20 |
|---|
| 341 | 341 | | (2) C |
|---|
| 342 | 342 | | ONSULTATION BEFORE ENTRY INTO 21 |
|---|
| 343 | 343 | | AGREEMENT.—Before entering into a trusted trade 22 |
|---|
| 344 | 344 | | partner agreement under section 5, the Trade Rep-23 |
|---|
| 345 | 345 | | resentative shall consult with— 24 |
|---|
| 346 | 346 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00012 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 347 | 347 | | ssavage on LAPJG3WLY3PROD with BILLS 13 |
|---|
| 348 | 348 | | •S 998 IS |
|---|
| 349 | 349 | | (A) the appropriate committees of Con-1 |
|---|
| 350 | 350 | | gress; and 2 |
|---|
| 351 | 351 | | (B) each other committee of the Senate 3 |
|---|
| 352 | 352 | | and the House of Representatives, and each 4 |
|---|
| 353 | 353 | | joint committee of Congress, that has jurisdic-5 |
|---|
| 354 | 354 | | tion over legislation involving a subject matter 6 |
|---|
| 355 | 355 | | that would be affected by the agreement. 7 |
|---|
| 356 | 356 | | (c) C |
|---|
| 357 | 357 | | ONSULTATIONWITHFEDERALAGENCIES.—In 8 |
|---|
| 358 | 358 | | the course of negotiations under section 5(a) for a trusted 9 |
|---|
| 359 | 359 | | trade partner agreement, the Trade Representative shall 10 |
|---|
| 360 | 360 | | inform and consult with any Federal agency having exper-11 |
|---|
| 361 | 361 | | tise in the matters being negotiated, including the Depart-12 |
|---|
| 362 | 362 | | ment of Health and Human Services. 13 |
|---|
| 363 | 363 | | (d) L |
|---|
| 364 | 364 | | IMITATION ONACTION.—Any duty elimination 14 |
|---|
| 365 | 365 | | or staged rate reduction provided for under section 5 may 15 |
|---|
| 366 | 366 | | be proclaimed only if the President— 16 |
|---|
| 367 | 367 | | (1) has obtained advice regarding the proposed 17 |
|---|
| 368 | 368 | | action from the appropriate advisory committees es-18 |
|---|
| 369 | 369 | | tablished under section 135 of the Trade Act of 19 |
|---|
| 370 | 370 | | 1974 (19 U.S.C. 2155) and the International Trade 20 |
|---|
| 371 | 371 | | Commission; 21 |
|---|
| 372 | 372 | | (2) has submitted to the appropriate commit-22 |
|---|
| 373 | 373 | | tees of Congress a report that sets forth— 23 |
|---|
| 374 | 374 | | (A) the action proposed to be proclaimed; 24 |
|---|
| 375 | 375 | | (B) the reasons for such action; and 25 |
|---|
| 376 | 376 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00013 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 377 | 377 | | ssavage on LAPJG3WLY3PROD with BILLS 14 |
|---|
| 378 | 378 | | •S 998 IS |
|---|
| 379 | 379 | | (C) the advice obtained under paragraph 1 |
|---|
| 380 | 380 | | (1); and 2 |
|---|
| 381 | 381 | | (3) has consulted with the appropriate commit-3 |
|---|
| 382 | 382 | | tees of Congress regarding the proposed action dur-4 |
|---|
| 383 | 383 | | ing the 60-day period on the date on which the 5 |
|---|
| 384 | 384 | | President has met the requirements under para-6 |
|---|
| 385 | 385 | | graphs (1) and (2). 7 |
|---|
| 386 | 386 | | (e) R |
|---|
| 387 | 387 | | EPORT TOCONGRESS.—Not later than 60 days 8 |
|---|
| 388 | 388 | | before the date on which the President enters into a trust-9 |
|---|
| 389 | 389 | | ed trade partner agreement with a trusted trade partner 10 |
|---|
| 390 | 390 | | under section 5, the President shall submit to Congress 11 |
|---|
| 391 | 391 | | a report describing— 12 |
|---|
| 392 | 392 | | (1) the nature and scope of the agreement; 13 |
|---|
| 393 | 393 | | (2) the proposed duration of the agreement; 14 |
|---|
| 394 | 394 | | (3) how and to what extent the agreement will 15 |
|---|
| 395 | 395 | | achieve the applicable purposes, policies, priorities, 16 |
|---|
| 396 | 396 | | and objectives of this Act; 17 |
|---|
| 397 | 397 | | (4) whether sufficient evidence exists dem-18 |
|---|
| 398 | 398 | | onstrating that— 19 |
|---|
| 399 | 399 | | (A) the trusted trade partner satisfies the 20 |
|---|
| 400 | 400 | | conditions under section 5(b); and 21 |
|---|
| 401 | 401 | | (B) the reciprocal elimination of existing 22 |
|---|
| 402 | 402 | | duties or other import restrictions of the trust-23 |
|---|
| 403 | 403 | | ed trade partner or the United States with re-24 |
|---|
| 404 | 404 | | spect to medical goods would contribute to the 25 |
|---|
| 405 | 405 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00014 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 406 | 406 | | ssavage on LAPJG3WLY3PROD with BILLS 15 |
|---|
| 407 | 407 | | •S 998 IS |
|---|
| 408 | 408 | | national security and public health of the 1 |
|---|
| 409 | 409 | | United States; and 2 |
|---|
| 410 | 410 | | (5) the proposed implementation of the agree-3 |
|---|
| 411 | 411 | | ment, including the general effect of the agreement 4 |
|---|
| 412 | 412 | | on existing laws. 5 |
|---|
| 413 | 413 | | (f) C |
|---|
| 414 | 414 | | ONGRESSIONAL RIGHTTOREVIEW ANDDIS-6 |
|---|
| 415 | 415 | | APPROVE.— 7 |
|---|
| 416 | 416 | | (1) I |
|---|
| 417 | 417 | | N GENERAL.—A trusted trade partner 8 |
|---|
| 418 | 418 | | agreement shall not take effect until— 9 |
|---|
| 419 | 419 | | (A) the proposed agreement has been sub-10 |
|---|
| 420 | 420 | | mitted to Congress, together with the report re-11 |
|---|
| 421 | 421 | | quired under subsection (e) with respect to that 12 |
|---|
| 422 | 422 | | agreement; and 13 |
|---|
| 423 | 423 | | (B) the review period required under para-14 |
|---|
| 424 | 424 | | graph (2) following the date on which the pro-15 |
|---|
| 425 | 425 | | posed agreement has been submitted to Con-16 |
|---|
| 426 | 426 | | gress under subparagraph (A) has been ex-17 |
|---|
| 427 | 427 | | hausted, during which period a joint resolution 18 |
|---|
| 428 | 428 | | is not enacted under paragraph (4). 19 |
|---|
| 429 | 429 | | (2) R |
|---|
| 430 | 430 | | EVIEW.— 20 |
|---|
| 431 | 431 | | (A) I |
|---|
| 432 | 432 | | NITIAL REVIEW.—Unless extended 21 |
|---|
| 433 | 433 | | under subparagraph (B) or (C), the review pe-22 |
|---|
| 434 | 434 | | riod under this paragraph with respect to a 23 |
|---|
| 435 | 435 | | trusted trade partner agreement is 30 days, 24 |
|---|
| 436 | 436 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00015 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 437 | 437 | | ssavage on LAPJG3WLY3PROD with BILLS 16 |
|---|
| 438 | 438 | | •S 998 IS |
|---|
| 439 | 439 | | during which time Congress shall review the 1 |
|---|
| 440 | 440 | | proposed agreement with respect to whether— 2 |
|---|
| 441 | 441 | | (i) the President failed or refused to 3 |
|---|
| 442 | 442 | | provide notice with respect to the agree-4 |
|---|
| 443 | 443 | | ment in accordance with subsection (a); 5 |
|---|
| 444 | 444 | | (ii) the President failed or refused to 6 |
|---|
| 445 | 445 | | consult with respect to the agreement in 7 |
|---|
| 446 | 446 | | accordance with subsections (b) and (c); 8 |
|---|
| 447 | 447 | | (iii) the President failed or refused to 9 |
|---|
| 448 | 448 | | submit to Congress a report with respect 10 |
|---|
| 449 | 449 | | to the agreement in accordance with sub-11 |
|---|
| 450 | 450 | | section (e); or 12 |
|---|
| 451 | 451 | | (iv) the President failed or refused to 13 |
|---|
| 452 | 452 | | demonstrate that the agreement would 14 |
|---|
| 453 | 453 | | achieve the applicable purposes, policies, 15 |
|---|
| 454 | 454 | | priorities, and objectives of this Act and 16 |
|---|
| 455 | 455 | | contribute to the national security and 17 |
|---|
| 456 | 456 | | public health of the United States. 18 |
|---|
| 457 | 457 | | (B) F |
|---|
| 458 | 458 | | URTHER REVIEW.—If, during the 30- 19 |
|---|
| 459 | 459 | | day period under subparagraph (A) with re-20 |
|---|
| 460 | 460 | | spect to a trusted trade partner agreement, one 21 |
|---|
| 461 | 461 | | House of Congress adopts a resolution stating 22 |
|---|
| 462 | 462 | | that the House of Congress wishes to further 23 |
|---|
| 463 | 463 | | review the proposed agreement, the review pe-24 |
|---|
| 464 | 464 | | riod under this paragraph with respect to the 25 |
|---|
| 465 | 465 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00016 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 466 | 466 | | ssavage on LAPJG3WLY3PROD with BILLS 17 |
|---|
| 467 | 467 | | •S 998 IS |
|---|
| 468 | 468 | | proposed agreement shall be extended by a pe-1 |
|---|
| 469 | 469 | | riod of 60 days, during which time the appro-2 |
|---|
| 470 | 470 | | priate committees of Congress shall engage the 3 |
|---|
| 471 | 471 | | President with respect to the proposed agree-4 |
|---|
| 472 | 472 | | ment and the failures or refusals of the Presi-5 |
|---|
| 473 | 473 | | dent specified under subparagraph (A). 6 |
|---|
| 474 | 474 | | (C) A |
|---|
| 475 | 475 | | DDITIONAL PERIOD.—If, during the 7 |
|---|
| 476 | 476 | | 60-day period under subparagraph (B) with re-8 |
|---|
| 477 | 477 | | spect to a trusted trade partner agreement, one 9 |
|---|
| 478 | 478 | | House of Congress adopts a resolution stating 10 |
|---|
| 479 | 479 | | that the House of Congress wishes to further 11 |
|---|
| 480 | 480 | | review the proposed agreement, the review pe-12 |
|---|
| 481 | 481 | | riod under this paragraph with respect to the 13 |
|---|
| 482 | 482 | | proposed agreement shall be further extended 14 |
|---|
| 483 | 483 | | by a period of 30 days. 15 |
|---|
| 484 | 484 | | (3) P |
|---|
| 485 | 485 | | ROCEDURES FOR CONSIDERING RESOLU -16 |
|---|
| 486 | 486 | | TIONS.—A resolution under subparagraph (B) or 17 |
|---|
| 487 | 487 | | (C) of paragraph (2)— 18 |
|---|
| 488 | 488 | | (A) in the Senate— 19 |
|---|
| 489 | 489 | | (i) may be introduced by any Member 20 |
|---|
| 490 | 490 | | of the Senate; 21 |
|---|
| 491 | 491 | | (ii) shall be referred to the Committee 22 |
|---|
| 492 | 492 | | on Finance; and 23 |
|---|
| 493 | 493 | | (iii) may not be amended; 24 |
|---|
| 494 | 494 | | (B) in the House of Representatives— 25 |
|---|
| 495 | 495 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00017 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 496 | 496 | | ssavage on LAPJG3WLY3PROD with BILLS 18 |
|---|
| 497 | 497 | | •S 998 IS |
|---|
| 498 | 498 | | (i) may be introduced by any Member 1 |
|---|
| 499 | 499 | | of the House; 2 |
|---|
| 500 | 500 | | (ii) shall be referred to the Committee 3 |
|---|
| 501 | 501 | | on Ways and Means or the Committee on 4 |
|---|
| 502 | 502 | | Rules; and 5 |
|---|
| 503 | 503 | | (iii) may not be amended by either 6 |
|---|
| 504 | 504 | | Committee; and 7 |
|---|
| 505 | 505 | | (C) the vote on passage of the resolution 8 |
|---|
| 506 | 506 | | shall occur immediately following the conclusion 9 |
|---|
| 507 | 507 | | of the debate on the trusted trade partner 10 |
|---|
| 508 | 508 | | agreement at issue and a single quorum call at 11 |
|---|
| 509 | 509 | | the conclusion of the debate. 12 |
|---|
| 510 | 510 | | (4) D |
|---|
| 511 | 511 | | ISAPPROVAL.—If, during the review period 13 |
|---|
| 512 | 512 | | required under paragraph (2) with respect to a 14 |
|---|
| 513 | 513 | | trusted trade partner agreement, a joint resolution 15 |
|---|
| 514 | 514 | | is enacted stating that Congress does not favor the 16 |
|---|
| 515 | 515 | | agreement, the agreement shall not take effect. 17 |
|---|
| 516 | 516 | | SEC. 7. MONITORING AND ENFORCEMENT OF CONTINUED 18 |
|---|
| 517 | 517 | | COMPLIANCE WITH TRUSTED TRADE PART-19 |
|---|
| 518 | 518 | | NER AGREEMENTS. 20 |
|---|
| 519 | 519 | | (a) M |
|---|
| 520 | 520 | | ONITORING.—The Trade Representative shall 21 |
|---|
| 521 | 521 | | periodically monitor compliance by a trusted trade partner 22 |
|---|
| 522 | 522 | | with the commitments and obligations of the partner 23 |
|---|
| 523 | 523 | | under a trusted trade partner agreement. 24 |
|---|
| 524 | 524 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00018 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 525 | 525 | | ssavage on LAPJG3WLY3PROD with BILLS 19 |
|---|
| 526 | 526 | | •S 998 IS |
|---|
| 527 | 527 | | (b) ACTIONS INRESPONSE TOFAILURETOCOM-1 |
|---|
| 528 | 528 | | PLY.— 2 |
|---|
| 529 | 529 | | (1) D |
|---|
| 530 | 530 | | ETERMINATION AND REPORT OF TRADE 3 |
|---|
| 531 | 531 | | REPRESENTATIVE.—If the Trade Representative de-4 |
|---|
| 532 | 532 | | termines that a trusted trade partner has failed to 5 |
|---|
| 533 | 533 | | satisfactorily implement, maintain, and enforce the 6 |
|---|
| 534 | 534 | | commitments and obligations of the partner under a 7 |
|---|
| 535 | 535 | | trusted trade partner agreement, the Trade Rep-8 |
|---|
| 536 | 536 | | resentative shall submit to the President a report 9 |
|---|
| 537 | 537 | | setting forth— 10 |
|---|
| 538 | 538 | | (A) the determination and the findings 11 |
|---|
| 539 | 539 | | that support the determination; and 12 |
|---|
| 540 | 540 | | (B) based on such findings, the rec-13 |
|---|
| 541 | 541 | | ommendations of the Trade Representative for 14 |
|---|
| 542 | 542 | | action or inaction under this subsection. 15 |
|---|
| 543 | 543 | | (2) D |
|---|
| 544 | 544 | | ETERMINATION OF PRESIDENT .—Not 16 |
|---|
| 545 | 545 | | later than 30 days after receiving a report under 17 |
|---|
| 546 | 546 | | paragraph (1) with respect to a trusted trade part-18 |
|---|
| 547 | 547 | | ner, the President shall— 19 |
|---|
| 548 | 548 | | (A) determine whether the President con-20 |
|---|
| 549 | 549 | | curs with the determination of the Trade Rep-21 |
|---|
| 550 | 550 | | resentative set forth in the report; and 22 |
|---|
| 551 | 551 | | (B) if the President concurs, determine 23 |
|---|
| 552 | 552 | | whether— 24 |
|---|
| 553 | 553 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00019 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 554 | 554 | | ssavage on LAPJG3WLY3PROD with BILLS 20 |
|---|
| 555 | 555 | | •S 998 IS |
|---|
| 556 | 556 | | (i) to suspend, withdraw, or prevent 1 |
|---|
| 557 | 557 | | the application of the trusted trade partner 2 |
|---|
| 558 | 558 | | agreement with the trusted trade partner; 3 |
|---|
| 559 | 559 | | (ii) to enter into a binding agreement 4 |
|---|
| 560 | 560 | | with the partner that commits the part-5 |
|---|
| 561 | 561 | | ner— 6 |
|---|
| 562 | 562 | | (I) to eliminate any burden or re-7 |
|---|
| 563 | 563 | | striction on the United States result-8 |
|---|
| 564 | 564 | | ing from the failure of the partner to 9 |
|---|
| 565 | 565 | | comply with the commitments and ob-10 |
|---|
| 566 | 566 | | ligations of the partner under a trust-11 |
|---|
| 567 | 567 | | ed trade partner agreement; and 12 |
|---|
| 568 | 568 | | (II) to provide the United States 13 |
|---|
| 569 | 569 | | with such compensatory trade benefits 14 |
|---|
| 570 | 570 | | as are negotiated between the Trade 15 |
|---|
| 571 | 571 | | Representative and the partner; or 16 |
|---|
| 572 | 572 | | (iii) to take such other actions as the 17 |
|---|
| 573 | 573 | | Trade Representative considers necessary 18 |
|---|
| 574 | 574 | | to encourage the partner to adhere to the 19 |
|---|
| 575 | 575 | | commitments and obligations of the part-20 |
|---|
| 576 | 576 | | ner under a trusted trade partner agree-21 |
|---|
| 577 | 577 | | ment, including suspending the exemption 22 |
|---|
| 578 | 578 | | of the partner from trade-restrictive meas-23 |
|---|
| 579 | 579 | | ures imposed with respect to medical goods 24 |
|---|
| 580 | 580 | | during a public health emergency. 25 |
|---|
| 581 | 581 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00020 Fmt 6652 Sfmt 6201 E:\BILLS\S998.IS S998 |
|---|
| 582 | 582 | | ssavage on LAPJG3WLY3PROD with BILLS 21 |
|---|
| 583 | 583 | | •S 998 IS |
|---|
| 584 | 584 | | (3) TIMELINE FOR ACTION .—If the President 1 |
|---|
| 585 | 585 | | determines under paragraph (2)(B) to take action, 2 |
|---|
| 586 | 586 | | the President shall implement that action by not 3 |
|---|
| 587 | 587 | | later than the date that is 15 days after the day on 4 |
|---|
| 588 | 588 | | which the President determines to take action under 5 |
|---|
| 589 | 589 | | that paragraph. 6 |
|---|
| 590 | 590 | | Æ |
|---|
| 591 | 591 | | VerDate Sep 11 2014 02:22 Mar 26, 2025 Jkt 059200 PO 00000 Frm 00021 Fmt 6652 Sfmt 6301 E:\BILLS\S998.IS S998 |
|---|
| 592 | 592 | | ssavage on LAPJG3WLY3PROD with BILLS |
|---|